Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00992238 · ClinicalTrials.gov registry record · Phase 1
A Relative Bioavailability Study of 100 mg Flavoxate Hydrochloride Tablets Under Fasting Conditions
A Phase 1 study, sponsored by Padagis.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT00992238 is a Phase 1 study that has completed, run by Padagis. The registered enrollment target is 48 participants.
The verdict
NCT00992238, a Phase 1 study, has completed, sponsored by Padagis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the relative bioavailability of Flavoxate Hydrochloride tablets 100mg manufactured by Paddock Laboratories, Inc., with that of Urispas® tablets 100mg by SmithKline Beecham Pharmaceuticals under fasting conditions.
Interventions
- DRUG Flavoxate Hydrochloride Tablets, 100mg
- DRUG Urispas® Tablets, 100mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00992238
The ClinicalTrials.gov registry entry for NCT00992238 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Padagis, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Flavoxate Hydrochloride Tablets, 100mg is the first listed.
NCT00992238 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00992238 about?
NCT00992238 is a clinical study titled "A Relative Bioavailability Study of 100 mg Flavoxate Hydrochloride Tablets Under Fasting Conditions". The purpose of this study is to compare the relative bioavailability of Flavoxate Hydrochloride tablets 100mg manufactured by Paddock Laboratories, Inc., with that of Urispas® tablets 100mg by SmithKline Beecham Pharmaceuticals under fasting conditions.
What is the current status of trial NCT00992238?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants.
What interventions are being tested in trial NCT00992238?
The interventions under investigation include: Flavoxate Hydrochloride Tablets, 100mg (DRUG), Urispas® Tablets, 100mg (DRUG).
Who is sponsoring clinical trial NCT00992238?
This trial is sponsored by Padagis, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.